Month: March 2022

GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health. The collaboration is centered around NexImmune’s artificial antigen presenting cells’ (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. Dr. Jeffrey S. Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center will guide the research and evaluation. “NexImmune is excited to have...

Plan to file U.S. IND for lead program FasTCAR-T GC012F for relapse and/or refractory multiple myeloma (RRMM) during second half of 2022 Allogeneic TruUCAR-T GC502 currently being investigated in a first-in-human investigator-initiated trial (IIT) in China in B-cell malignancies with early data to be presented at AACR 2022 Well-funded with cash runway into 2024 Management to host conference call at 8:00 a.m. ET todayPALO ALTO, Calif. and SUZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported fourth quarter and full year unaudited financial results for the period ended December 31, 2021, and provided...

First patient treated in the ASCEND study evaluating the potential benefit of investigational higher dose nusinersen in children, teens and adults previously treated with Evrysdi® (risdiplam) Baseline characteristics indicate all nine infants and toddlers enrolled in RESPOND had suboptimal clinical status in ≥2 areas after receiving Zolgensma® (onasemnogene abeparvovec); there were no new safety findings with subsequent SPINRAZA® (nusinersen) treatment New NURTURE results continue to show the potential long-term benefit of early treatment before SMA symptom onset, with 92 percent of participants now able to walk alone, most in age-appropriate timelinesCAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN UNITED STATES CALGARY, Alberta, March 14, 2022 (GLOBE NEWSWIRE) — Pieridae Energy Limited (“Pieridae” or the “Company”) (PEA.TO) will release its fourth quarter and year-end 2021 results on Thursday, March 24, 2022 prior to markets opening. Chief Executive Officer Alfred Sorensen, Chief Operating Officer Darcy Reding and Interim Chief Financial Officer Adam Gray will discuss the financial results, Company developments and forward-looking strategy at 8:30 a.m. (MDT) /10:30 a.m. (EDT). Members of the investment community, shareholders and other interested parties are invited to participate by calling toll-free 1-877-800-8195, or international dial in 615-622-8082. Please dial in 10 minutes prior to the start of the call. No pass code is required. A live...

SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Caren Deardorf to the company’s board of directors. Ms. Deardorf has broad experience in biotechnology, building on over 20 years at Biogen where she led commercial efforts for neurological diseases, including rare congenital disorders. Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, stated, “Caren’s unique understanding of the importance of building commercial and corporate brands globally, while remaining focused on the needs of patients, was important to us, especially as we begin our transition...

Esposito Brings Strong Innovation and Electronics Solutions Business ExpertiseShyft Group – Carl Esposito The Shyft Group announced that Carl Esposito has been appointed to the Company’s Board of Directors, effective March 14, 2022.NOVI, Mich., March 14, 2022 (GLOBE NEWSWIRE) — The Shyft Group, Inc. (NASDAQ: SHYF), the North American leader in specialty vehicle manufacturing, assembly and upfit for the commercial, retail, and service specialty vehicle markets, today announced that Carl Esposito has been appointed to the Company’s Board of Directors, effective March 14, 2022. In addition, Ronald Harbour, 65, a member of the Shyft Board of Directors since 2009, will retire from the board effective as of the Company’s annual meeting of shareholders in May 2022. Esposito, 54, brings decades of experience in leading strategic...

— NUZYRA® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% increase over Prior Year, and $37.9 Million from the Initial Procurement of NUZYRA under the BARDA Bioshield Contract — Approval of NUZYRA in China for treatment of ABSSSI and CABP in December 2021; Triggered a $6 Million Milestone Payment from Zai Lab BOSTON, March 14, 2022 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2021. “We are extremely proud of the 76% year-over-year growth in the core NUZYRA commercial business despite continued challenges from the ongoing COVID-19 pandemic. Our performance this year reflects the important...

– 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline were measured across all three dosing cohorts, signifying the oral therapy has the potential to address both the root cause of LGMD2i and drive functional improvements for patients– Average of 70% reduction in creatine kinase (CK), a key marker of muscle breakdown, after 90 days of treatment and average 77% reduction after 180 days– Increase in velocity in the 10-meter walk test (10MWT) at day 90 and 180, which is an improvement over the decline in velocity seen in the natural history data– If the development program is successful, BridgeBio believes BBP-418 could be the first approved therapy for the treatment of patients with LGMD2i– BridgeBio to host investor call on March 14, 2022 at 8:00 AM ET PALO ALTO, Calif.,...

Topline data from VIITAL™ expected in the third quarter of 2022 NEW YORK and CLEVELAND, March 14, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL™ study. The objective of VIITAL™ is to evaluate the safety and effectiveness of Abeona’s investigational EB-101 product for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. Large chronic wounds typically do not heal spontaneously and inflict the greatest pain and clinical burden on RDEB patients. Large chronic wounds treated in VIITAL™ measured greater...